Companies / Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc.
Nasdaq: TRVICIK 1563880NEW HAVEN, CT
Financials
Ownership
142.5M shares outstanding · as of Jul 31, 2026
Ownership
| 10%+ / strategic | 73.48% | 104,686,249 |
| Institutions | 87.08% | 124,067,341 |
| Public float | 0.00% | 0 |
Reported holdings exceed shares outstanding — public float shown as 0; some positions may overlap or lag.
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 20
View all →| Insider | % of shares | Shares |
|---|---|---|
Baskett Forest10% owner | 8.61% | 12,273,280 |
Behbahani Ali10% owner | 8.61% | 12,273,280 |
Chang Carmen10% owner | 8.61% | 12,273,280 |
Florence Anthony A. Jr.10% owner | 8.61% | 12,273,280 |
Makhzoumi Mohamad10% owner | 8.61% | 12,273,280 |
New Enterprise Associates 16, L.P.10% owner | 8.61% | 12,273,280 |
Sandell Scott D10% owner | 8.61% | 12,273,280 |
Walker Paul Edward10% owner | 8.61% | 12,273,280 |
Cassella James VChief Development Officer | — | — |
Colangelo DominickDirector | — | — |
Institutional holders 188
View all →| Holder | Value | % of shares |
|---|---|---|
| $208.04M | 7.83% | |
| $165.54M | 9.28% | |
| $128.45M | 7.20% | |
| $81.38M | 4.56% | |
| $80.56M | 4.52% | |
| $63.79M | 3.58% | |
| $56.46M | 2.12% | |
| $47.31M | 2.78% | |
| $47.16M | 2.64% | |
| $42.62M | 2.39% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q2 2026 as of | BlackRock, Inc. 13F manager | Add | Common stock | $19.19M | +1.0M +10.16% | 11,155,026 7.83% of shares | medium |
| Q2 2026 as of | State Street Corporation 13F manager | Add | Common stock | $11.05M | +592K +24.33% | 3,027,315 2.12% of shares | medium |
| Q4 2025 as of | Bank of America Corp /De 13F manager | Trim | Common stock | $-9.29M | -742K -40.39% | 1,094,851 0.77% of shares | medium |
| Q1 2026 as of | Orbimed Advisors LLC 13F manager | Trim | Common stock | $-8.78M | -736K -23.08% | 2,454,400 1.72% of shares | medium |
| Q1 2026 as of | Marshall Wace, LLP 13F manager | Trim | Common stock | $-7.33M | -615K -13.42% | 3,966,019 2.78% of shares | medium |
| Q1 2026 as of | Prudential Financial Inc 13F manager | Trim | Common stock | $-6.38M | -534K -97.32% | 14,726 0.01% of shares | medium |
| Q4 2025 as of | Barclays PLC 13F manager | Add | Common stock | $4.58M | +366K +168.65% | 582,653 0.41% of shares | low |
| Q1 2026 as of | Geode Capital Management, LLC 13F manager | Add | Common stock | $4.36M | +365K +15.14% | 2,778,231 1.95% of shares | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Vanguard Group Inc | Passive13G/A | — |
| Vanguard Group Inc | Passive13G | — |
| Rubric Capital Management LP | Passive13G/A | — |
| Fmr LLC | Passive13G | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| TRVI | — | 89532M101 |